REGENXBIO (NASDAQ:RGNX) rose 9.70% on June 23, 2026, as FDA feedback supported an accelerated Navsunli filing path, with shares closing at $9.95.

Key Highlights

  • Rose 9.70%: REGENXBIO closed at $9.95 on June 23 after moving $0.88 per share.
  • Catalyst: During the session, FDA feedback supported an accelerated Navsunli filing path.
  • Company: REGENXBIO develops gene therapies using its adeno-associated virus platform.
  • Session: The stock finished at $9.95, while the available company record showed a disclosed catalyst for the move.

REGENXBIO (NASDAQ:RGNX) rose 9.70% on June 23, 2026, closing at $9.95 after a $0.88 per-share move. The session’s advance came as FDA feedback supported an accelerated Navsunli filing path, based on the available company disclosures and trading context.

Favourable FDA feedback supported an accelerated-approval filing path for Navsunli (NAV-0200) in wet age-related macular degeneration, with multiple analysts raising price targets following the regulatory communication. REGENXBIO's AAV gene therapy platform has been a multi-year investment thesis, and the regulatory clarity on Navsunli represented a meaningful milestone for a programme that had faced prior uncertainty.

REGENXBIO develops gene therapies using its adeno-associated virus platform.

The stock remains substantially below its historical highs.

The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.

The shares closed at $9.95 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.

For the June 23 close, the defining facts were the 9.70% advance, the $9.95 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.